
N-Zyme Biomedical
- N-Zyme Biomedical just raised $4.6M (Series A) on Jul 21
A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.
About
N-Zyme Biomedical is a clinical-stage biotechnology company developing first-in-class therapies that target pepsin, a key driver of tissue damage in reflux disease. The company's lead drug candidate, NZ-101, is currently in Phase 2 clinical trials for laryngopharyngeal reflux (LPR) and proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD). N-Zyme Biomedical aims to transform the treatment of reflux disease by addressing its underlying causes rather than solely focusing on acid suppression.
Show 6 more similar companies
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Biotech
Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
Shares Biotechnology, Drug Discovery
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Pharmaceuticals
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to N-Zyme Biomedical?
People comparing tools land here. Get listed beside these.
All funding rounds
Tech stack
Detected on nzymebio.com, last scanned 15 Nov 2026. Run your own scan
- Analytics
- Hotjar
- CMS / Builders
- Webflow
- CDN
- Cloudflare
- Email provider
- Google Workspace
- Video / media
- YouTube
Benchmarking
See how your site ranks against 16,849 startups
N-Zyme Biomedical sits in the 12th percentile for Domain Rating. Check where yours lands, free.
Check your Domain RatingN-Zyme Biomedical has a Domain Rating of 7, the 12th percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Bottom 25%
Check yoursAgent Readiness
Above median
Scan yoursSite Speed
Below median
PageSpeedData Trust
Above median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
N-Zyme Biomedical scores 43. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentAI visibility
Get read by ChatGPT, Claude and Perplexity
List your startup, then track where you show up in AI answers.
AI reads of this profile
Last 14 days, from server logs
Get notified when N-Zyme Biomedical changes
Used N-Zyme Biomedical? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is N-Zyme Biomedical growing?
Yes, fast. Our data shows it raised $4.6M in a Series A in July 2026.
Are there companies like N-Zyme Biomedical?
Yes. We list 6 companies like N-Zyme Biomedical, including Moderna, Degron Therapeutics and Epicrispr Biotechnologies.
Is N-Zyme Biomedical trustworthy and reputable?
StartupHub's Data Trust & Reputation score for N-Zyme Biomedical is 66 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has N-Zyme Biomedical raised?
N-Zyme Biomedical has raised a total of $5M in funding. The most recent round on record is Series A.
How many employees does N-Zyme Biomedical have?
N-Zyme Biomedical has approximately 5 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for N-Zyme Biomedical:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch N-Zyme Biomedical and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini


